首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis
【24h】

Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis

机译:遗传和功能分析暗示NUDT11,HNF1B和SLC22A3基因与前列腺癌的发病机理有关

获取原文
获取原文并翻译 | 示例
           

摘要

One of the central goals of human genetics is to discover the genes and pathways driving human traits. To date, most of the common risk alleles discovered through genome-wide association studies (GWAS) map to nonprotein-coding regions. Because of our relatively poorer understanding of this part of the genome, the functional consequences of trait-associated variants pose a considerable challenge. To identify the genes through which risk loci act, we hypothesized that the risk variants are regulatory elements. For each of 12 known risk polymorphisms, we evaluated the correlation between risk allele status and transcript abundance for all annotated protein-coding transcripts within a 1-Mb interval. A total of 103 transcripts were evaluated in 662 prostate tissue samples [normal (n = 407) and tumor (n = 255)] from 483 individuals [European Americans (n = 233), Japanese (n = 127), and African Americans (n = 123)]. In a pooled analysis, 4 of the 12 risk variants were strongly associated with five transcripts (NUDT11, MSMB, NC0A4, SLC22A3. and HNF1B) in historically normal tissue (P ≤ 0.001). Although associations were also observed in tumor tissue, they tended to be more attenuated. Previously, we showed that MSMB and NC0A4 participate in prostate cancer pathogenesis. Suppressing the expression of NUDT11. SLC22A3, and HNF1B influences cellular phenotypes associated with tumor-related properties in prostate cancer cells. Taken together, the data suggest that these transcripts contribute to prostate cancer pathogenesis.
机译:人类遗传学的主要目标之一是发现驱动人类特征的基因和途径。迄今为止,通过全基因组关联研究(GWAS)发现的大多数常见风险等位基因都映射到非蛋白质编码区域。由于我们对基因组这一部分的了解相对较差,因此与性状相关的变体的功能后果带来了相当大的挑战。为了确定风险基因座起作用的基因,我们假设风险变异体是调控元件。对于12种已知的风险多态性中的每一种,我们评估了1-Mb间隔内所有带注释的蛋白质编码转录本的风险等位基因状态与转录本丰度之间的相关性。在483个个体中的662个前列腺组织样本[正常(n = 407)和肿瘤(n = 255)]中对总共103个转录本进行了评估[欧美人(n = 233),日本人(n = 127)和非裔美国人( n = 123)]。在汇总分析中,历史正常组织中12个风险变异中的4个与5个转录本(NUDT11,MSMB,NC0A4,SLC22A3和HNF1B)密切相关(P≤0.001)。尽管在肿瘤组织中也观察到关联,但是它们倾向于更弱化。先前,我们显示了MSMB和NC0A4参与前列腺癌的发病机理。抑制NUDT11的表达。 SLC22A3和HNF1B影响与前列腺癌细胞中肿瘤相关特性相关的细胞表型。两者合计,数据表明这些转录本有助于前列腺癌的发病机理。

著录项

  • 来源
  • 作者单位

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;

    Department of Biostatistics and Computational Biology,Dana-Farber Cancer Institute, Boston, MA 02115;

    Department of Medical Oncology,Dana-Farber Cancer Institute, Boston, MA 02115 Cancer Program Broad Institute of Harvard and MIT, Cambridge, MA 02142;

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;

    Department of Medical Oncology,Dana-Farber Cancer Institute, Boston, MA 02115 Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 Department of Urology, Jikei University School of Medicine, Minato-ku, Tokyo 105-8461, Japan;

    Department of Urology, Lefrak Center of Robotic Surgery and Prostate Cancer Institute, Weill Cornell Medical College, New York, NY 10065;

    Department of Urology, Lefrak Center of Robotic Surgery and Prostate Cancer Institute, Weill Cornell Medical College, New York, NY 10065;

    Department of Urology, Lefrak Center of Robotic Surgery and Prostate Cancer Institute, Weill Cornell Medical College, New York, NY 10065;

    Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;

    Centre for Molecular Medicine Norway (NCMM), University of Oslo, N-0349 Oslo,Norway Departments of Urology Oslo University Hospitals, N-0370 Oslo, Norway Departments of Cancer Prevention, Oslo University Hospitals, N-0370 Oslo, Norway;

    Uro-Oncology Research Group, Cancer Research United Kingdom, Cambridge Research Institute, Cambridge CB2 ORE, United Kingdom;

    Uro-Oncology Research Group, Cancer Research United Kingdom, Cambridge Research Institute, Cambridge CB2 ORE, United Kingdom;

    Department of Urology, Jikei University School of Medicine, Minato-ku, Tokyo 105-8461, Japan;

    Department of Urology, Jikei University School of Medicine, Minato-ku, Tokyo 105-8461, Japan;

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115 Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;

    Department of Medicine and Urology, Tulane Cancer Center,Tulane University School of Medicine, New Orleans, LA 70112;

    Department of Urology, Jikei University School of Medicine, Minato-ku, Tokyo 105-8461, Japan;

    Department of Urology, Lefrak Center of Robotic Surgery and Prostate Cancer Institute, Weill Cornell Medical College, New York, NY 10065;

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 Cancer Program Broad Institute of Harvard and MIT, Cambridge, MA 02142 Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;

    Department of Medicine Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115 Medical and Population Genetics Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    expression quantitative trait loci; prostate cancer risk snps; multi-ethnic;

    机译:表达数量性状基因座前列腺癌风险多民族;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号